Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2418753 | 0.91 | HTT (0.51) | HTTGAACYP1A2CYP2C9PKM | |
| SCHEMBL10002459 | 0.85 | HTT (0.54) | HTTGAASMN1; SMN2KMT2ACHRNB4 | |
| Pyridine SCHEMBL27489987 | 0.84 | CYP1A2 (0.64) | HTTGAACYP1A2CYP2C9PKM | |
| SCHEMBL28632092 | 0.83 | HTT (0.56) | HTTGAASMN1; SMN2KMT2ACHRNB4 | |
| SCHEMBL1974134 | 0.81 | GRM2 (0.53) | HTTSMN1; SMN2KMT2AALDH1A1CHRNB2 | |
| SCHEMBL22289159 | 0.81 | HTT (0.60) | HTTGAACYP1A2CYP2C9TDP1 | |
| SCHEMBL2411539 | 0.80 | HTT (0.49) | HTTSMN1; SMN2KMT2ACHRNB4CHRNA3 | |
| SCHEMBL11068453 | 0.79 | TBXAS1 (0.65) | HTTGAACYP1A2CYP2C9PKM | |
| SCHEMBL127395 | 0.79 | CYP1A2 (0.78) | GAACYP1A2CYP2C9PKMCYP2C19 | |
| SCHEMBL43054 | 0.79 | CYP1A2 (0.78) | GAACYP1A2CYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-12 | — | — | US | disclosed |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-05 | — | — | US | disclosed |
| US-8030316-B2 | Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine | BIOVITRUM AB (PUBL) (SE) | 2011-10-04 | — | — | US | disclosed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| US-4404020-A | Certain esters of 2-[(2,6-dichloro-3-pyridyl)oxy]propionic acid, compositions containing same and their herbicidal properties | CIBA-GEIGY CORPORATION (US) | 1983-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | HTT 1383/4885GAA 2463/4885CYP1A2 4681/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | HTT 1383/4885GAA 2463/4885CYP1A2 4681/4885 |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | HTT 1009/4885GAA 1056/4885CYP1A2 3724/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | HTT 1383/4885GAA 2463/4885CYP1A2 4681/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | HTT 1383/4885GAA 2463/4885CYP1A2 4681/4885 |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | HTT 1383/4885GAA 2463/4885CYP1A2 4681/4885 |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | HTT 2502/4885GAA 763/4885CYP1A2 478/4885 |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | SUCNR1, HTR5A, HTR2C | HTT 89/4885GAA 3153/4885CYP1A2 335/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | HTT 1383/4885GAA 2463/4885CYP1A2 4681/4885 |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, KCNJ11 | HTT 2367/4885GAA 3619/4885CYP1A2 232/4885 |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | HTT 222/4885GAA 3399/4885CYP1A2 40/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | HTT 3022/4885GAA 806/4885CYP1A2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.